12 completed, 2 recruiting, 2 terminated, 2 withdrawn. 20 Phase 1, 8 Phase 2.
Follow midostaurin: new trials by email Literature Review of midostaurin trials Research Report on midostaurin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia Venetoclax in association with 3+7 and midostaurin - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Bordeaux | 41 | 2026-09-01 | 2026-07-24 |
| Revumenib in Combination With 7+3 + Midostaurin in AML Revumenib, Midostaurin, Cytarabine - Acute Myeloid Leukemia, AML, Adult | Phase 1 | Recruiting | Richard Stone, MD | 22 | 2024-12-06 | 2026-03-25 |
| Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia CPX-351, Midostaurin, Busulfan - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Guenther Koehne | 2022-07-05 | 2024-10-01 | |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Technische Universität Dresden | 214 | 2020-09-04 | 2025-09-08 |
| HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. HDM201, Midostaurin - AML, Adult | Phase 1 | Terminated | Insel Gruppe AG, University Hospital Bern | 2 | 2020-07-13 | 2022-10-06 |
| A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia CPX-351, Venetoclax, Midostaurin - Acute Myeloid Leukemia | Phase 1 | Completed | Jazz Pharmaceuticals | 57 | 2019-12-02 | 2023-10-16 |
| HDM201 Added to CT in R/R or Newly Diagnosed AML HDM201, cytarabine, anthracycline - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-11-15 | 2020-01-09 | |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride - Acute Myeloid Leukemia | Phase 1 | Completed | Uma Borate | 21 | 2019-03-13 | 2026-05-15 |
| A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) LGH447, LGH447 + midostaurin - AML and High Risk MDS | Phase 1 | Completed | Novartis Pharmaceuticals | 70 | 2014-03-20 | 2020-12-17 |
| Midostaurin (PKC412) for Locally Advanced Rectal Cancer Midostaurin - Adenocarcinoma of the Rectum | Phase 1 | Completed | Massachusetts General Hospital | 19 | 2011-08-01 | 2018-12-12 |
| PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function Midostaurin - Hepatic Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 43 | 2011-03-07 | 2021-05-12 |
| PKC412 and 5-Azacytidine 5-azacytidine, PKC412 - Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 54 | 2011-03-01 | 2018-10-16 |
| Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine - Leukemia, Myeloid, Acute | Phase 1 | Completed | Washington University School of Medicine | 11 | 2010-11-01 | 2013-07-23 |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia midostaurin, Bortezomib, mitoxantrone hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following | Phase 1 | Completed | Alison Walker | 34 | 2010-08-01 | 2016-07-06 |
| Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia combination therapy using decitabine and midostaurin - Acute Myeloid Leukemia | Phase 1 | Completed | University of Kansas | 16 | 2010-03-01 | 2013-03-26 |
| A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia midostaurin - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 22 | 2009-09-01 | 2015-12-22 |
| Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia midostaurin, azacitidine, bone marrow aspiration - Untreated Adult Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Brenda Cooper, MD | 34 | 2009-07-01 | 2022-06-30 |
| RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS RAD001, PKC412 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Active not recruiting | Richard Stone, MD | 29 | 2009-01-01 | 2026-03-25 |
| PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia cytarabine, daunorubicin hydrochloride, midostaurin - Acute Myeloid Leukemia (AML) | Phase 1 | Completed | Novartis Pharmaceuticals | 69 | 2004-02-01 | 2020-12-19 |
| PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2) Itraconazole, PKC412 - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 144 | 2002-01-30 | 2017-08-11 |
Leukemia, Myeloid, Acute (17) · Myelodysplastic Syndromes (5) · Congenital Abnormalities (2) · Leukemia (2) · Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Rectal Neoplasms (1)
Novartis Pharmaceuticals (6) · Richard Stone, MD (2) · Alison Walker (1) · Brenda Cooper, MD (1) · Guenther Koehne (1) · Insel Gruppe AG, University Hospital Bern (1) · Jazz Pharmaceuticals (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Technische Universität Dresden (1) · Uma Borate (1) · University Hospital, Bordeaux (1) · University of Kansas (1) · Washington University School of Medicine (1)
United States (16) · Germany (4) · France (3) · Italy (2) · Netherlands (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Japan (1) · Lithuania (1) · Romania (1) · Sweden (1) · Switzerland (1)
Richard Stone, MD (2) · Alison Walker, MD (1) · Brenda Cooper, MD (1) · Camille Abboud, M.D. (1) · Casey Williams, PharmD (1) · Guenther Koehne, MD. PhD (1) · Jorge Cortes, MD (1) · Theodore S Hong, MD (1) · Thomas Pabst, Prof (1) · Uma Borate, M.D. (1)
PMID 22627678, PMID 24488798, PMID 26784138, PMID 40932876, PMID 41488889
2008 (1), 2018 (1)